好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Unilateral Primary CNS Vasculitis in a Child Associated with Increased ICP and Treated with Maximal Medical Therapy and Decompressive Hemicraniectomy
Child Neurology and Developmental Neurology
P4 - Poster Session 4 (5:30 PM-6:30 PM)
7-039
We present a case of a 6-year-old boy with new-onset seizures and altered mental status associated with multifocal right hemispheric lesions resulting from primary CNS vasculitis. Unique features of the case including unilateral involvement and aggressive medical and surgical management are discussed.

Primary CNS vasculitis or primary angiitis of the CNS (PACNS) is a rare vascular inflammatory brain disease, often associated with variable neurological manifestations and a lengthy diagnostic evaluation. Secondary causes of CNS vasculitis and other inflammatory brain disorders must be excluded and a definite diagnosis relies on tissue biopsy. Some forms of PACNS can be rapidly progressive and life-threatening, further complicating the diagnostic and treatment process. 

Case report featuring clinical presentation, laboratory, pathology, and neuroimaging results, and discussion of diagnostic/treatment decision-making.

A 6-year-old previously healthy boy with intermittent headaches developed focal seizures and altered mentation. CSF had marked pleocytosis (WBC  139 cells/mm3) and elevated protein (299 mg/dL). MRI brain demonstrated multifocal areas of T2 hyperintense signal, restricted diffusion, and microhemorrhage involving the deep and superficial white matter of the right hemisphere. Despite maximal osmotic, sedative, and immune-directed therapies, he exhibited worsening cerebral edema and midline shift with persistently elevated intracranial pressures. He underwent decompressive hemicraniectomy and open brain biopsy showing perivascular lymphocytic cuffing and lymphocytes in the vessel walls, consistent with PACNS. He was treated with cyclophosphamide with gradual improvement in cerebral edema, and underwent cranioplasty four weeks after hemicraniectomy. His left hemiparesis improved significantly over one month in inpatient rehabilitation and he regained the ability to ambulate independently.

Our case demonstrates an unusual presentation of PACNS in a child given unilateral involvement and fulminant course.  Management of this child involved a multidisciplinary team of providers and complex diagnostic and therapeutic decision-making, ultimately resulting in a favorable outcome.

Authors/Disclosures
Cynthia X. Wang, MD (Children's Dallas Neurology)
PRESENTER
Dr. Wang has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Benjamin M. Greenberg, MD, FAAN (UT Southwestern Medical Center) Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Greenberg has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Sanofi/Genzyme. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for IQVIA. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Greenberg has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Clene. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for IQVIA. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Greenberg has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Siegel Rare Neuroimmune Association. Dr. Greenberg has or had stock in GenrAb.Dr. Greenberg has or had stock in Clene.Dr. Greenberg has received intellectual property interests from a discovery or technology relating to health care. Dr. Greenberg has received publishing royalties from a publication relating to health care.